RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:424046

Acinar cell carcinoma of pancreas

low confidenceDisorder

Also known as: Pancreatic acinar cell carcinoma

Publications

1,170

Trials

28

Interventional, condition-specific

Researchers

1,541

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

A very rare, malignant, epithelial tumor of the pancreas characterized, macroscopically, by a usually large, well-circumscribed, fully or partially encapsulated, solid mass, often with hemorrhage, necrosis and cystic changes, in any portion of the pancreas and, histologically, by neoplastic cells with variable degrees of differentiation and morphology, ranging from acinar structures similar to normal pancreatic acini to large sheets of poorly differentiated neoplastic cells. Presenting symptoms are typically non-specific and include abdominal pain, weight loss, vomiting, nausea, and/or, less commonly, jaundice. Immunohistochemical evidence of acinar-specific products is observed. Association with Lynch syndrome, familial adenomatous polyposis, and pancreatic panniculitis has been reported.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (9)

Pancreatic acinar cell cancer · acinar cell adenocarcinoma of pancreas · acinar cell adenocarcinoma of the pancreas · acinar cell carcinoma of pancreas · acinar cell carcinoma of the pancreas · carcinoma of pancreatic acinar cell · pancreas acinar cell adenocarcinoma · pancreatic acinar cell adenocarcinoma · pancreatic acinar cell carcinoma

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    1,170 matched papers (678 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPresent

    28 matched on ClinicalTrials.gov (2 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

1,170

1,170 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

1,170 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

678 in the last 10 years · low confidence

Phrase hits: 1,170 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,541

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Li C5 papers · 2025

    Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio.

    Papers in Europe PMC
  2. 02
    Liu Y5 papers · 2026

    Department of Satistics, Hebei University, Baoding, 071000, China.

    Papers in Europe PMC
  3. 03
    Simon R5 papers · 2025

    Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg.

    Papers in Europe PMC
  4. 04
    Bernreuther C4 papers · 2025

    Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg.

    Papers in Europe PMC
  5. 05
    Burandt E4 papers · 2025

    Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg.

    Papers in Europe PMC
  6. 06
    Büscheck F4 papers · 2025

    Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg.

    Papers in Europe PMC
  7. 07
    Dum D4 papers · 2025

    Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg.

    Papers in Europe PMC
  8. 08
    Fraune C4 papers · 2025

    Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg.

    Papers in Europe PMC
  9. 09
    Gorbokon N4 papers · 2025

    Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg.

    Papers in Europe PMC
  10. 10
    Hinsch A4 papers · 2025

    Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

28

interventional trials for this specific condition

28 interventional trials matched this specific condition name; 2 currently recruiting in our sample. 2 trials are registered for acinar cell carcinoma, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 27 July 2026

28 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 95.5th percentile).

low confidence · 95.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

28 interventional trials matched after quoted-phrase search and title/condition post-filter.

Broader category: acinar cell carcinoma

2

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Acinar cell carcinoma of pancreas" OR "Acinar cell carcinoma of the pancreas" OR "Pancreatic acinar cell carcinoma" OR "Pancreatic acinar cell cancer" OR "acinar cell adenocarcinoma of pancreas" OR "acinar cell adenocarcinoma of the pancreas" OR "carcinoma of pancreatic acinar cell" OR "carcinoma of the pancreatic acinar cell" OR "pancreas acinar cell adenocarcinoma" OR "pancreatic acinar cell adenocarcinoma"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Acinar cell carcinoma of pancreas" OR "Acinar cell carcinoma of the pancreas" OR "Pancreatic acinar cell carcinoma" OR "Pancreatic acinar cell cancer" OR "acinar cell adenocarcinoma of pancreas" OR "acinar cell adenocarcinoma of the pancreas" OR "carcinoma of pancreatic acinar cell" OR "carcinoma of the pancreatic acinar cell" OR "pancreas acinar cell adenocarcinoma" OR "pancreatic acinar cell adenocarcinoma"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 28 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"acinar cell carcinoma"

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (1170) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity

Ingested 2026-07-27T15:55:47.942Z